DPL Red Light Therapy — Full Review

DPL (Deep Penetrating Light) is one of the older names in consumer red light therapy, with its devices occupying a specific niche: FDA-cleared, pain-focused, and clinically referenced. The brand is owned by LED Technologies Inc., the same company behind the reVive Light Therapy range, and has been selling photobiomodulation devices since the mid-2000s — well before the current wave of red light therapy panels and masks flooded the market.

This review covers the two primary DPL devices still widely available: the DPL II and the DPL Flex Pad. Both are positioned as pain relief and joint therapy devices rather than general wellness products, and both carry FDA clearance for specific indications. The question is whether the clinical positioning and regulatory status justify what you get in terms of actual light output and value.

The DPL Product Range

DPL II

The DPL II is a rigid handheld panel containing an array of LEDs arranged in a flat pad format. It is designed to be placed directly against the skin over the treatment area.

Key Specifications:

• Wavelengths: 660 nm (red) and 880 nm (infrared)
• LED count: 72 LEDs (combination of red and infrared)
• Treatment area: Approximately 18 x 10 cm
• Power source: Mains-powered (AC adaptor)
• Treatment time: 15–20 minutes per session (manufacturer recommendation)
• FDA clearance: Class II medical device, cleared for temporary relief of minor muscle and joint pain, arthritis pain, muscle spasm, and increased local blood circulation

The 880 nm wavelength is worth noting. Most modern consumer panels use 850 nm for the near-infrared component. The 880 nm used by DPL is slightly deeper into the infrared spectrum and sits within the absorption range of cytochrome c oxidase, though the evidence base for 850 nm is considerably larger in the published literature.

DPL Flex Pad

The DPL Flex Pad is a flexible, wrap-style version designed to conform to curved body surfaces — knees, shoulders, elbows, and the lower back.

Key Specifications:

• Wavelengths: 660 nm (red) and 880 nm (infrared)
• LED count: 60 LEDs
• Treatment area: Approximately 18 x 18 cm (square flexible pad)
• Power source: Mains-powered
• Treatment time: 15–20 minutes per session
• Flexibility: The pad bends to wrap around joints and curved body areas
• FDA clearance: Same Class II clearance as DPL II

The flexible form factor is the Flex Pad’s primary advantage over the rigid DPL II. For knee, shoulder, and elbow treatment, the ability to wrap the device around the joint and secure it with the included strap means the LEDs maintain closer, more consistent contact with the skin surface, which directly affects energy delivery.

Irradiance and Power Output

This is where DPL devices show their age. LED Technologies does not prominently publish irradiance figures for the DPL range, which is itself a concern in a market where competitors like PlatinumLED, Mito Red Light, and Hooga now provide detailed irradiance data.

Based on available information and independent assessments, DPL devices deliver approximately 25–40 mW/cm² at the treatment surface. This is adequate for therapeutic dosing over the recommended 15–20 minute treatment window (delivering roughly 22–48 J/cm² total energy density), but it is substantially lower than modern panels that deliver 80–200+ mW/cm² at comparable distances.

The lower irradiance means longer treatment times to achieve the same energy dose. A modern panel delivering 100 mW/cm² achieves 6 J/cm² in one minute; the DPL II takes approximately 2.5–4 minutes to deliver the same dose. Over a full treatment session, the DPL devices deliver adequate energy, but they are less time-efficient than current-generation devices.

The FDA Clearance Factor

DPL’s primary marketing advantage is its FDA clearance. This is worth understanding in context.

What FDA Clearance Means

The DPL devices are cleared as Class II medical devices through the 510(k) pathway. This means the FDA has determined that the devices are “substantially equivalent” to a legally marketed predicate device. Specifically, they are cleared for:

• Temporary relief of minor muscle and joint pain and stiffness
• Temporary relief of arthritis pain
• Temporary relief of muscle spasm
• Temporary increase of local blood circulation

What FDA Clearance Does Not Mean

• It does not mean the FDA has independently verified the clinical efficacy of these specific devices
• It does not mean DPL devices are more effective than non-FDA-cleared devices
• It does not mean the devices have undergone clinical trials (510(k) clearance requires demonstration of equivalence, not original clinical evidence)

Many newer red light therapy panels (Mito Red Light, PlatinumLED, Hooga) choose not to pursue FDA clearance because the process is expensive and because they prefer not to limit their marketing claims to the narrow medical indications that clearance requires. This does not mean those devices are less effective — it means the companies have made a different regulatory strategy decision.

The FDA clearance is most relevant for users who want the reassurance of a regulatory pathway, or for healthcare professionals recommending devices to patients who may require that level of formal approval.

Clinical Evidence

DPL markets its devices with reference to the broader photobiomodulation evidence base. The wavelengths used (660 nm and 880 nm) do fall within established therapeutic windows:

Bjordal et al. (2003) in their systematic review published in the BMJ (327:1215) found that photobiomodulation with wavelengths in the red and near-infrared range significantly reduced pain in musculoskeletal conditions including tendinopathy, osteoarthritis, and chronic joint disorders.

Chow et al. (2009) in The Lancet (374(9705):1897-1908) confirmed that photobiomodulation reduces pain across multiple chronic pain conditions, with dose ranges of 1–4 J per treatment point showing the most consistent effects.

Hamblin (2017) in Photochemistry and Photobiology (93(5):1199-1201) reviewed the mechanisms of photobiomodulation and confirmed that 660 nm and wavelengths in the 800–900 nm range are the two primary absorption peaks of cytochrome c oxidase, validating the dual-wavelength approach used by DPL.

However, no published clinical trial has been conducted using DPL devices specifically. The clinical references apply to photobiomodulation broadly, not to these particular products.

DPL vs Kineon Move+

The most relevant comparison for DPL is the Kineon Move+ Pro, which also targets joint pain specifically:

Feature	DPL II / Flex Pad	Kineon Move+ Pro
Wavelengths	660 nm + 880 nm (LED)	808 nm (laser) + 650 nm (LED)
Technology	LED only	Laser diodes + LEDs
FDA cleared	Yes (Class II)	Yes (Class II)
Battery powered	No (mains only)	Yes
Treatment time	15–20 minutes	15 minutes
Portability	Limited (power cable)	Fully portable
Form factor	Pad (rigid or flex)	Wearable strap
Irradiance	~25–40 mW/cm²	~50–80 mW/cm² (LED), higher at laser points
Price	£80–150	£350–400

Kineon represents the modern evolution of exactly the problem DPL was designed to solve: targeted joint and muscle pain therapy. The Kineon uses laser diodes that deliver higher concentrated energy to specific tissue depths, runs on battery power, and is genuinely wearable during daily activities.

The DPL devices are less expensive and carry the same FDA clearance category, but the technology is a generation behind. The mains power requirement and lower irradiance are real practical limitations in daily use.

DPL vs Modern Full-Size Panels

For users considering DPL for general pain management, a comparison with entry-level full-size panels is instructive:

Feature	DPL Flex Pad	Hooga HG300	Mito Red Light MitoMIN
Wavelengths	660 + 880 nm	660 + 850 nm	660 + 850 nm
Irradiance	~25–40 mW/cm²	~80–100 mW/cm²	~80+ mW/cm²
Treatment area	18 x 18 cm	30 x 18 cm	30 x 15 cm
FDA cleared	Yes	No	No
Versatility	Pain therapy only	Full body, skin, pain	Full body, skin, pain
Price	£80–150	£100–150	£150–200

At similar price points, modern panels deliver significantly higher irradiance across larger treatment areas. The DPL Flex Pad’s only meaningful advantage is its flexibility and FDA clearance.

Strengths

• FDA-cleared (Class II) — provides regulatory reassurance for medical use
• Established brand — over 15 years in the market
• Dual wavelengths (660 nm + 880 nm) — covers both red and near-infrared therapeutic windows
• Flex Pad version wraps around joints effectively
• Affordable at £80–150 compared with premium targeted devices
• Simple operation — no apps, modes, or settings to configure
• Designed specifically for pain — focused use case rather than trying to do everything

Weaknesses

• Low irradiance compared with modern panels (~25–40 mW/cm² vs 80–200+ mW/cm²)
• Mains-powered only — no battery option limits portability
• No published irradiance data from the manufacturer
• No device-specific clinical trials — relies on general PBM evidence
• Dated technology — the LED arrays are lower density and lower output than current-generation devices
• 880 nm wavelength has a smaller evidence base than the 850 nm used by most competitors
• Limited treatment area — even the Flex Pad covers only 18 x 18 cm
• No pulsing modes — continuous wave only

Who Should Buy DPL

Ideal for:

• Users who specifically want an FDA-cleared device for pain relief
• Healthcare professionals who need a device with regulatory clearance to recommend to patients
• Budget-conscious buyers wanting a targeted pain therapy device under £150
• Elderly users who want simple, no-configuration operation
• Those treating specific small areas (knee, elbow, wrist) where the Flex Pad can wrap effectively

Not ideal for:

• Users wanting maximum irradiance and shortest treatment times (modern panels are superior)
• Anyone needing portable, battery-powered treatment (Flexbeam or Kineon are better choices)
• Those wanting full-body treatment capability (buy a full-size panel)
• Users interested in skin rejuvenation, hair growth, or other non-pain applications
• Buyers who want transparent, published irradiance testing data

Verdict

DPL occupies an increasingly difficult position in the market. When these devices were introduced, they were among the first consumer-accessible photobiomodulation products, and the FDA clearance was a genuine differentiator. Today, the competitive landscape has changed fundamentally.

The technology is adequate — the wavelengths are therapeutically valid, the energy delivery over a full treatment session falls within the optimal dose range, and the devices are well-built for their age. But the irradiance is low by modern standards, the lack of battery power limits convenience, and the price-to-performance ratio is no longer competitive against entry-level panels from Hooga, Mito Red Light, or Bestqool.

The FDA clearance remains the primary reason to choose DPL. If regulatory status matters to you — whether for professional credibility, insurance documentation, or personal reassurance — DPL provides that. For everyone else, the same money buys significantly more light output from a modern panel.

Rating: 5/10 — Therapeutically valid wavelengths and FDA clearance in a package that is now outperformed on irradiance, versatility, and value by almost every modern competitor.

This review is editorially independent. Product details and prices were accurate at the time of writing and may change. See our methodology for how we assess devices.